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TSLC1e skeletal protein expressed in various organs, and is associated with tumor
suppressor in lung cancer-1 (TSLC1) in vitro. Although involvement of 4.1B in the intercellular junctions and
tumor-suppression was suggested, some controversial results posed questions to the general tumor-
suppressive function of 4.1B and its relation to TSLC1 in vivo. In this study, the expression of 4.1B and its
interaction with TSLC1 were examined in rodent adrenal gland, and the involvement of 4.1B in tumorigenesis
and the effect of 4.1B deﬁciency on TSLC1 distribution were also investigated using rodent pheochromo-
cytoma and 4.1B-knockout mice. Although plasmalemmal immunolocalization of 4.1B was shown in
chromafﬁn cells of rodent adrenal medulla, expression of 4.1B was maintained in developed pheochromo-
cytoma, and morphological abnormality or pheochromocytoma generation could not be found in 4.1B-
deﬁcient mice. Furthermore, molecular interaction and colocalization of 4.1B and TSLC1 were observed in
mouse adrenal gland, but the immunolocalization of TSLC1 along chromafﬁn cell membranes was not
affected in the 4.1B-deﬁcient mice. These results suggest that the function of 4.1B as tumor suppressor might
signiﬁcantly differ among organs and species, and that plasmalemmal retention of TSLC1 would be
maintained by molecules other than 4.1B interacting in rodent chromafﬁn cells.
© 2009 Elsevier B.V. All rights reserved.1. IntroductionProteins associated with membrane skeletons are essential for
structural integrity via cellular morphogenesis and intercellular
adhesion, and also clearly related to intracellular signal transduction
[1–4]. Protein 4.1B (4.1B), which is also known as differentially
expressed in adenocarcinoma of the lung-1 (DAL-1), is one of the
proteins associated with the membrane skeleton. It was originally
identiﬁed as a molecule composing the junctional complex between
axons and myelinating cells in the paranodal and juxtaparanodal
regions of the peripheral and central nervous systems [5–7]. The
distribution of 4.1B along cell membranes in organs outside the
nervous system, such as kidney, intestine and pancreatic islets,
suggest that 4.1B would also be involved in intercellular junctions
via transmembranous molecules in different organs [8–11]. On the
other hand, 4.1B was identiﬁed as a molecule whose expression
decreased in non-small cell lung carcinoma [12]. Several studies in81 55 273 6743.
l rights reserved.different cancers such as non-small cell lung carcinoma, meningioma,
ependymoma, breast cancer, colorectal carcinoma and prostate cancer
supported the tumor-suppressive function of 4.1B in general [13–17].
Tumor suppressor in lung cancer-1 (TSLC1) is another tumor
suppressor responsible for the development of various cancers, and
is also known as IGSF4/Necl-2/SgIGSF/RA175/SynCAM1. Direct binding
of 4.1B to TSLC1 was postulated to mediate the interaction between
TSLC1 and actin membrane skeletons, and impairment of the 4.1B-
TSLC1 systemwas found in lung and breast cancers [18–23]. Although
these results showed signiﬁcant involvement of 4.1B in multi-organ
carcinogenesis and related tumor-suppressive functions of 4.1B and
TSLC1, genetic loss of 4.1B in mice did not result in abnormal
development or higher frequency of tumor generation [24]. In
addition, reduced expression of TSLC1, but not 4.1B, was found in
the generation of rat hepatocellular carcinoma [25]. These discordant
results pose questions concerning the general tumor-suppressive
function of 4.1B, as well as its relationship with TSLC1 in vivo.
In the present study, expression of 4.1B and its interaction with
TSLC1 were examined in rodent adrenal gland. The involvement of
4.1B in tumorigenesis and the effect of 4.1B deﬁciency on TSLC1
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specimens and our 4.1B-knockout mouse model.
2. Materials and methods
2.1. Derivation of rodent pheochromocytoma and 4.1B-knockout mice
All animal experiments were performed in accordance with the
guidelines of the Animal Care and Use Committee, University of
Yamanashi. Rat spontaneous pheochromocytomas were obtained
from Wistar and Sprague–Dawley rats, as described previously [26].
A mouse model of multiple endocrine neoplasia type 2B (MEN2B) was
produced by substituting methionine at the codon 919 of Ret
oncogene to threonine, as described previously [27]. The MEN2B
mice were inbred on C57BL/6J background, and used for histological
analyses. For 4.1B-knockout mice, DNA fragments located upstream
and downstream of the 4.1B gene exons 2 and 3 were obtained from
genomic DNA of 129/Sv embryonic stem cells by PCR using TaKaRa LA
Taq (TaKaRa Bio, Otsu, Shiga, Japan). The fragments were directly
cloned and sequenced with a TOPO XL PCR cloning kit (Invitrogen,
Carlsbad, CA) to be N99.8% identical to the original 129/Sv mouse
genomic sequences. The fragments were then subcloned to the
PGKneolox2DTA vector [28], and ﬂanked a neoR expression cassette
(Fig. 1A). This targeting vector replaces a 2.8-kb genomic fragment
containing exons 2 and 3. The lineated construct was electroporated
into 129/S4-derived AK7 embryonic stem (ES) cells [28], and colonies
were selected with G418. Homologous recombination events were
screened by the PCR, using a set of primers corresponding to the Neo
gene and a genomic sequence outside the targeting construct. ES cells
were injected into blastocysts of C57BL/6 mice, and the chimeric mice
generated were crossed with C57BL/6 mice for several generations.
2.2. Genotyping of 4.1B-knockout mice by Southern blotting and PCR
First, we genotyped wild type and heterozygote mice obtained
from the chimeric mice. For genotyping, Southern blotting was
performed with the digoxigenin application system according to the
manufacturer's instructions (Roche Diagnostic Systems, Basel, Swit-Fig. 1. (A) Construction of the targeting vector (Vector) and organization of the 4.1B gene of w
resistance gene; ATG1 and ATG2: the translation initiation codons of 4.1B; Probe: a region of a
reaction for genotyping of offspring. (B) In the Southern blotting, using the 1-kb region upst
provided a 5.8-kb fragment (arrowhead), whereas that of heterozygous mice (+/−) provided
allele (WT) produces an approximately 0.5-kb DNA fragment in wild type and heterozygous
fragment in heterozygous and homozygous mice (−/−).zerland). The DNA obtained from liver biopsy was digested with XbaI
and blotted on Hybond-N+ (GE Healthcare, Buckinghamshire, Eng-
land). A probe was produced and labeled with digoxigenin through
PCR of a region located in the short arm (Fig. 1A), using a PCR DIG
Probe Synthesis Kit (Roche Diagnostic Systems, Basel, Switzerland).
The blotted DNA and the probe were hybridized with Easy Hyb, anti-
DIG antibody, blocking solution and CDP Star (Roche Diagnostic
Systems, Basel, Switzerland). The XbaI digestion generated a 5.8-kb
band in the wild type allele and a 2.0-kb band in the mutant allele
following homologous recombination (Fig. 1A, B).
Subsequent offspring were genotyped by PCR, using DNA obtained
from tail biopsy and primers of 5′-AGGTGACTTCGCAGTGTTCC-3′, 5′-
ATTGGAAGCCTTGAGCAGCA-3′ and 5′-TATCGCCTTCTTGACGAGTTC-3′.
A PCR reaction for the wild type allele produced a 0.5-kb DNA
fragment in wild type and heterozygous mice, and for the mutant
allele produced a 0.5-kb DNA fragment in heterozygous and homo-
zygous mice (Fig. 1A, C).
2.3. Antibodies
The following antibodies were commercially obtained: a rabbit
polyclonal anti-4.1B (ProteinExpress, Chiba, Japan), which was
produced as described previously [7], goat anti-synaptosomal-
associated protein of 25 kDa (SNAP-25; Santa Cruz Biotechnology,
Santa Cruz, CA, USA), rabbit anti-neural cell adhesion molecule
(NCAM; Chemicon, Temecula, CA, USA) and chicken anti-TSLC1
(clone 3E1; Medical and Biological Laboratories, Nagoya, Japan).
Secondary antibodies and streptavidin conjugated with Alexa ﬂuor-
escent dye were obtained from Invitrogen (Carlsbad, CA). Biotinylated
goat anti-rabbit and donkey anti-rabbit antibodies were obtained
from Vector laboratories (Burlingame, CA) and chicken antibodies
were obtained from Jackson immunoresearch laboratories (West
Grave, PA, USA).
2.4. Western blotting and immunoprecipitation analyses
The tissue of C57BL/6 mice at 8 weeks of age was homogenized in
Tris buffer (40 mM Tris–HCl [pH 7.4], 150 mM NaCl, 1 mM EDTA,ild type (Wild) and mutant mice (Mutant). DTA: diphtheria toxin; Ex: exon; neoR: neo-
digoxigenin-labeled probe for Southern blotting; bidirectional arrows: the target of PCR
ream of exon 2 as a probe, the genomic DNA of wild type mice (+/+) digested with XbaI
5.8-kb (arrowhead) and 2.0-kb (arrow) fragments. (C) The PCR reaction for wild type
mice, whereas that for the mutant allele (Mu) produces an approximately 0.5-kb DNA
Fig. 2. (A) Western blotting analysis of 4.1B/differentially expressed in adenocarcinoma
of the lung-1 (4.1B) in mouse brain (lane 1) and adrenal gland (lane 2). Speciﬁc bands
with molecular weights of approximately 130 and 110 kDa can be detected in both
organs (arrowheads). (B, C) In situ hybridization for 4.1B mRNA in rat adrenal gland.
Reaction products can be observed in adrenal medulla (Me) with the antisense probe (B,
arrows), but not with the sense probe (C, arrows). Co: adrenal cortex. Bars: 50 μm.
Fig. 3. Immunostaining for 4.1B in mouse (A–D) or rat (E, F) adrenal gland. A differential
interference contrast image of the area in (A) is shown in (B). Immunoreactivity of 4.1B
is detected in adrenal medulla (Me; A, arrows), and fascicular immunostaining (A,
double arrowheads) is also detected in the cortex (Co). At higher magniﬁcation, the
immunoreactivity in the cortex (A inset, double arrowhead) is frequently detected
around blood vessels (V). In the medulla, the immunoreactivity appears to localize
along cell membranes of chromafﬁn cells (C, arrows), and the fascicular staining is also
observed (D, large arrowheads). The immunoreactivity cannot be detected on the side
facing blood vessels (D, small arrowheads). In rat adrenal gland (E), similar
immunostaining for 4.1B along cell membranes (F, arrows) and fascicular immunos-
taining (F, large arrowheads) are observed. Asterisks: endothelial cells. Bars: 30 μm in A,
B, and E; 10 μm in C, D and F.
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inhibitor cocktail (Sigma, St. Louis, MO, USA), incubated at 4 °C for 1 h,
and centrifuged at 10,000 g for 20 min. Protein concentration was
measured using a BCA Protein Assay Kit (Pierce Chemicals, Rockford,
IL). For western blotting, the supernatants were mixed with an equal
amount of Laemmli sample treatment buffer, and SDS-PAGE and
western blotting were performed with the anti-4.1B or TSLC1
antibodies, as described previously [15]. For the immunoprecipitation
assays, the supernatant was diluted with an equal volume of Tris
buffer and incubated with protein G-Sepharose (GE Healthcare Bio-
Science, Piscataway, NJ) for 1 h, with 15 μg anti-4.1B antibody or
puriﬁed rabbit control IgG (Zymed Laboratories, South San Francisco,
CA) overnight, and with the protein G-Sepharose for 1 h. Thereafter,
the beads were washed with Tris buffer containing 0.5% TritonX-100
three times for 10 min each, and boiled in Laemmli sample treatment
buffer. SDS-PAGE and western blotting were performed as described
above.
2.5. In situ hybridization
Adrenal gland tissue of 8-weeks-oldWistar rats was quickly frozen
by plunging into isopentane–propane cryogen, as described pre-
viously [29]. Then 14 μm-thick sections were mounted on glass slides,
air-dried, brieﬂy incubated in chloroform, and ﬁxed with 4%
paraformaldehyde in phosphate buffered saline (PBS) for 20 min.Both anti-sense and sense complementary RNA probes against 4.1B
mRNA were prepared, quantiﬁed and standardized, as described
previously [6]. They were then treated with 0.2 M hydrogen chloride
for 20 min and 1 mg/l protease K in PBS at 37 °C for 15 min. After post-
ﬁxation in 4% paraformaldehyde in PBS for 10 min, they were
incubated in 0.1 M triethanolamine (pH 8.0) containing 0.25% acetic
anhydride for 20 min, in 2× saline-sodium citrate (SSC) with 50%
formamide at 55 °C for 30 min, and in Hybridization buffer (Nippon
Gene, Tokyo, Japan) containing approximately 200 ng/ml sense or
anti-sense probe at 55 °C for 16 h. The sections were washed in 4× SSC
at 55 °C for 5 min and in 2× SSC containing 50% formamide for 30 min,
and incubated in NTE buffer (500 mM NaCl, 10 mM Tris–HCl, 1 mM
Fig. 4. (A–C) Immunoelectron micrographs for 4.1B in mouse adrenal medulla. The immunoreaction products are detected along cell membranes of chromafﬁn cells facing adjacent
chromafﬁn cells (A, B, arrows) and unmyelinated nerve ﬁbers (C, arrows) but not along those facing endothelial cells (B, arrowheads). The immunoreactivity is also detected in
unmyelinated neuronal ﬁbers (C, arrowheads). Asterisk: an endothelial cell. Nu: a nucleus of a chromafﬁn cell; V: a blood vessel; SC: a Schwann cell. Bars: 50 μm. (D–F) Double
immunoﬂuorescence staining for 4.1B (green) and SNAP-25 (red) in mouse adrenal medulla. Immunoreactivity of 4.1B can be detected in chromafﬁn cells strongly (D–F, arrows) or
weakly (D–F, arrowheads) immunopositive for SNAP-25. Bar: 20 μm.
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Japan) at 37 °C for 30 min. They were then washed in 2× SSC for
15 min, and in 0.2× SSC for 15 min. After a brief wash in Tris–saline
buffer (100 mM Tris–HCl, 150 mM NaCl, pH 7.5), they were incubated
with blocking solution (2% bovine serum albumin in Tris–saline
buffer) for 1 h, with alkaline phosphatase-conjugated anti-digox-
igenin antibody (Roche, Penzberg, Germany) in blocking solution for
1 h, and with visualization buffer (100 mM Tris–HCl, 100 mM NaCl,
50 mM MgCl2, pH 9.5) containing 0.05 mg/ml 5-bromo-4-chloro-3-
indolylphosphate and 0.1 mg/ml nitroblue tetrazolium (Kirkegaard
and Perry laboratories, Guildford, UK) for approximately 12 h. They
were brieﬂy counterstained with 0.1% methylgreen and embedded in
glycerol.
2.6. Immunohistochemistry
Rat pheochromocytoma was resected, ﬁxed in 10% buffered
formalin, and embedded in parafﬁn, as described previously [26].
Tissue preparation of other specimens and immunohistochemistry
were performed as described previously [30]. Brieﬂy, following
perfusion with buffered 2% paraformaldehyde, adrenal glands of
adult C57BL/6, MEN2B model mice, 4.1B-knockout mice, and Wistar
rats were removed and embedded in parafﬁn or OCT compound. The
adrenal sections on glass slides were irradiated in a microwave oven.
The sections for diaminobenzidine and immunoﬂuorescence staining
were incubated in 1% hydrogen peroxide and 0.1% Triton X-100 in PBS,respectively. The sections were treated with a blocking solution
containing 2% bovine serum albumin (Sigma, St. Louis, MO) in PBS,
primary antibodies in the blocking solution, and secondary antibodies
conjugated with biotin or Alexa in the blocking solution with or
without TO-PRO-3 (Invitrogen, Carlsbad, CA, USA). Immunocontrol
sections were prepared by omitting the primary antibody. The
sections for immunoﬂuorescence microscopy were embedded in
Vectashield containing DAPI (Vector Laboratories. Burlingame, CA,
USA) and observed with a light microscope (BX-61; Olympus, Tokyo,
Japan) or with a confocal laser scanning microscope (FV1000;
Olympus, Tokyo, Japan). The other sections were visualized with the
avidin–biotin complex and diaminobenzidine, and observed under
the light microscope. Immunostaining for tyrosine hydroxylase and S-
100 protein was performed as described previously [26].
2.7. Electron microscopy
Immunoelectron microscopy was performed as described pre-
viously [31]. Brieﬂy, sections of mouse adrenal gland were immunos-
tained for 4.1B with diaminobenzidine, and sequentially post-ﬁxed
with buffered 2.5% glutaraldehyde and 1% osmium tetroxide. The
sections were dehydrated in ethanol, embedded into epoxy resin by
the conventional inverted capsule method, sectioned at a thickness of
70 nm. They were then observed with a transmission electron
microscope (H-7500; Hitachi, Ibaragi, Japan). For the ultrastructural
analyses of 4.1B-knockout mice, mice were transcardially perfused
Fig. 5. (A,B) Western blotting (A, lanes a–d) and immunoprecipitation analyses (B, lanes 4.1, Co) for tumor suppressor in lung cancer-1 (TSLC1) in mouse adrenal glands. The western
blotting for TSLC1 shows single bands (A, arrowhead) in adrenal gland (A, lane a), kidney (A, lane b), and lung (A, lane c), but not in heart (A, lane d), although actin is detected in all
organs. A band (B, arrowhead) can be detected following immunoprecipitation with the anti-4.1B/differentially expressed in adenocarcinoma of the lung-1 (4.1B) antibody (B, lane
4.1) but not with the control IgG (B, lane Co). (C, D) Immunostaining for TSLC1 in mouse adrenal gland. The immunostained section (D) is also shown as a differential interference
contrast image (C). The immunoreactivity of TSLC1 is observed in adrenal medulla (Me; C, D, arrows), and appears to localize along cell membranes of chromafﬁn cells (D, inset,
arrows). Co: adrenal cortex. Bars: 50 μm. (E–H) Double immunoﬂuorescence staining for 4.1B (green) and TSLC1 (red) in mouse adrenal medulla. Cellular nuclei are labeled with
TOPRO3 (blue). Immunoreactivity of TSLC colocalizes with that of 4.1B on cell membranes of chromafﬁn cells (E–H, arrows). Bar: 20 μm.
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phate buffer, and the collected adrenal gland specimens were
embedded, sectioned, stained and analyzed as described previously
[32]. All statistical comparisons were conducted utilizing a two-sided
Student's t-test, and difference with pb0.05 was considered
signiﬁcant.
3. Results
Two isoforms of 4.1B are reported to be expressed in rat brain
tissue [7]. In the western blot analyses of 4.1B using rat adrenal gland
and brain tissue, two bands with similar molecular weights were
detected in both organs (Fig. 2A). The lower band corresponds to a
smaller isoform lacking the 5′ terminal region [33]. In situ hybridiza-
tion for 4.1B mRNA was also conducted in the rat adrenal gland, and
hybridization signals for 4.1B could be detected in the adrenal medulla
with an antisense probe (Fig. 2B), but not with a sense probe (Fig. 2C).
In the immunohistochemical analysis, immunoreactivity of 4.1B was
mainly localized in the adrenal medulla (Fig. 3A, B), and fascicular
immunostaining was also observed in the adrenal cortex (Fig. 3A). The
fascicular immunostaining was frequently observed around blood
vessels (Fig. 3A), and considered to represent unmyelinated nerve
ﬁbers [9]. There was no immunostaining for 4.1B in the immunocon-
trol sections (data not shown). At higher magniﬁcation, the immunor-
eactivity appeared to distribute along the cell membranes of
chromafﬁn cells in the adrenal medulla (Fig. 3C). The fascicular
immunostaining similar to that detected in cortex was also observed
among the chromafﬁn cells (Fig. 3D). In the chromafﬁn cells, the
immunoreactivity of 4.1B was not detected on the side facing the
blood vessels, which was characterized by spaces delimited by
endothelial cells (Fig. 3D). Similar ﬁndings were also observed in rat
adrenal glands as well (Fig. 3E, F). Immunoelectron microscopyshowed that the immunoreaction products for 4.1B were localized
along cell membranes of chromafﬁn cells not in contact with the
endothelial cells (Fig. 4A, B). The immunoreaction products were also
observed on the unmyelinated axolemma (Fig. 4C). In the double
immunoﬂuorescence staining with SNAP-25, which predominantly
immunolocalizes in noradrenergic cells of the adrenal medulla [34],
the immunoreactivity of 4.1B was observed in both adrenergic and
noradrenergic cells of the mouse adrenal medulla (Fig. 4D–F). These
results suggest that 4.1B in rodent adrenal medulla is localized along
cell membranes of all chromafﬁn cells.
TSLC1 expression was also examined and compared with 4.1B in
the mouse adrenal glands. TSLC1 expression has been reported
previously in kidney and lung tissue [35]. In western blot analyses of
mouse adrenal glands using an anti-TSLC1 antibody, bands with the
same molecular weight as those in mouse kidney and lung tissue
were observed (Fig. 5A). Additionally, a band could be detected by
western blotting against TSLC1 following the immunoprecipitation
assay with the anti-4.1B antibody (Fig. 5B). The immunostaining for
TSLC1 was predominantly observed in the adrenal medulla, and it
appeared to immunolocalize along cell membranes of chromafﬁn
cells (Fig. 5C, D). There was no immunostaining for TSLC1 in the
immunocontrol sections (data not shown). Double immunoﬂuores-
cence labeling for 4.1B and TSLC1 conﬁrmed that 4.1B and TSLC1 co-
localized on cell membranes of chromafﬁn cells (Fig. 5E–H). These
results suggest that in the mouse adrenal medulla, TSLC1 interacts
with 4.1B, and is distributed along the cell membranes of chromafﬁn
cells.
Given the expression of 4.1B and its interaction with TSLC1, the
relationship between the loss of 4.1B and tumorigenesis was
examined in the adrenal medulla. First, loss of 4.1B expression in
tumors was investigated immunohistochemically using the rat
spontaneous pheochromocytoma [26]. In rat pheochromocytomas
Fig. 6. (A–D) Immunostaining for 4.1B/differentially expressed in adenocarcinoma of the lung-1 (4.1B) in the rat spontaneous pheochromocytoma. Strong immunoreactivity of 4.1B
can be detected along cell membranes (A, B, arrowheads). The tumor is immunopositive for tyrosine hydroxylase (TH; C, arrowheads) but not for S100 (D, arrowheads). Co: adrenal
cortex. HE: hematoxylin–eosin. Bars: 30 μm. (E–H) Immunostaining for 4.1B in the pheochromocytoma developed in a MEN2B homozygous mouse. As in normal adrenal medulla
(Me) of wild type mice (WT; E, F), strong immunoreactivity of 4.1B can be detected in pheochromocytoma developed in adrenal gland of the homozygous mouse (Homo; G, H,
arrowheads). Bars: 50 μm.
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negative for S-100, immunostaining for 4.1B could be clearly observed
on cell membranes as seen in normal chromafﬁn cells (Fig. 6A–D).
Spontaneous pheochromocytomas obtained from 20 rats were
examined, and immunoreactivity for 4.1B was found to be detected
in all tumors, although it was decreased in some limited areas of 5tumor specimens. However, considering the possibility that the
genetic background of pheochromocytomas in rats is different from
that in human [36], pheochromocytomas of MEN2B model mice
generated by mutation in Ret oncogene were also investigated. In this
model, a small fraction of heterozygous mice (Met919Thr/Met919)
developed diffuse hyperplasia and pheochromocytoma, whereas most
Fig. 7. (A) Western blot analysis of 4.1B/differentially expressed in adenocarcinoma of the lung-1 (4.1B) in brain of wild type (+/+) or homozygote (−/−) mice. The speciﬁc bands with
molecular weights of approximately 130 and 110 kDa (arrows) can be detected in +/+ mice, but not in −/− mice. The amount of protein loaded in each well was 5 μg. (B–E)
Immunostaining for neural cell adhesion molecule (NCAM; B, C) and 4.1B (D, E) in serial sections of adrenal glands obtained from +/+ (B, D) or −/− (C, E) littermates. Adrenal medulla
(Me) can be distinguished from adrenal cortex (Co) by its positive immunostaining for NCAM (B, C, arrowheads). Immunoreactivity of 4.1B is observed in adrenal medulla of +/+ mice
(D, arrowheads), but absent in −/−mice (E, arrowheads). Bars: 30 μm. (F, G) Light micrographs of adrenal glands obtained from +/+ (F) or −/− (G) mice and stained with hematoxylin–
eosin. Me: adrenal medulla; Co: adrenal cortex. Bars: 200 μm; 50 μm in insets. (H, I) Electron micrographs of chromafﬁn cells in adrenal gland of +/+ (H) or −/− (I) mice. Areas marked
with rectangles are shown at higher magniﬁcation in insets. Opposed arrowheads: intercellular spaces between chromafﬁn cells. Bars: 500 nm. (J–Q) Double immunoﬂuorescence
labeling of NCAM (green) and tumor suppressor in lung cancer-1 (TSLC1; red) in adrenal glands of +/+ (J–M) or −/− (N–Q) mice. Immunolocalization of NCAM and TSLC1 along cell
membranes of chromafﬁn cells (arrows) and in nerve ﬁbers (arrowheads), observed in +/+ mice, is not changed in −/− mice. Bars: 30 μm.
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cytomas at the ages of 6–10 months [27]. Therefore, immunohisto-
chemistry for 4.1B was performed in the adrenal medulla of 5
homozygote and 3 wild type (Met919/Met919) MEN2B model mice at
6 months of age. There was no histological abnormality in the adrenal
gland of any of the wild type mice (Fig. 6E). By contrast, in the adrenal
medulla of all homozygous mice, normal polyhedral secretory cells
were replaced by abnormal cells with higher density of nuclei and less
volume of basophilic cytoplasm, and their mass mostly compressed
the surrounding adrenal cortex (Fig. 6G). This morphological appear-
ance was suggestive of pheochromocytoma development in most of
the homozygous mice, as reported previously [27]. In the pheochro-
mocytomas of the homozygotes, the immunostaining of 4.1B was also
strongly observed in all examined tumors, as obtained in normal
adrenal medulla of wild type (Fig. 6F, H).
Adrenal glands of 4.1B-knockout mice were further examined for
the development of tumors in the adrenal medulla. The 4.1B-deﬁcient
mice were born and developed normally without any apparent
difference from wild type littermates, as reported previously in
another 4.1B-knockout model [24]. First, lack of 4.1B expression was
conﬁrmed with western blotting in brain tissue, and bands reﬂecting
the expression of 4.1B in brain tissue of wild type mice were not
observed in those of homozygous mice (Fig. 7A). The expression of
4.1B protein was also immunohistochemically examined on cryosec-
tions of adrenal glands. In the adrenal medulla, immunoreactivity of
4.1B, which was clearly observed inwild type mice, was not present in
the homozygous mice, as determined by immunostaining for NCAM
[37] (Fig. 7B–E). However, the histological and ultrastructural analyses
of adrenal glands in the 4.1B-knockout mice revealed no signiﬁcant
difference between the homozygous mice and wild type littermates;
the sizes of the cortex and medulla were not signiﬁcantly different,
and no apparent changes indicating abnormal proliferation of
chromafﬁn cells could be observed in the adrenal medulla up to the
age of 18 months (Fig. 7F, G). In addition, although 4.1B is mainly
immunolocalized along cell membranes of chromafﬁn cells, their
ultrastructures were not changed in the knockoutmice (Fig. 7H, I), and
the intercellular spaces were not signiﬁcantly different in the
quantitative comparison (Mean±SD; 15.6±1.3 nm for wild type
mice; 15.7±1.6 nm for knockout mice; N=40, pN0.05). Considering
the potential involvement of 4.1B in the linkage of TSLC1 to cell
membranes via the actin cytoskeleton, immunostaining for TSLC1was
also investigated in the adrenal medulla. Immunoreactivity of TSLC1
was colocalized with that of NCAM along cell membranes of
chromafﬁn cells without any translocation or decrease, and thus
immunostaining of TSLC1 appeared to be unchanged in mutant and
wild type littermates of 4.1B-knockout mice (Fig. 7J–Q).
4. Discussion
In the present study, localization of 4.1B along cell membranes, and
its co-localization and association with TSLC1, were found for the ﬁrst
time in rodent adrenal medulla in vivo. These results support the
previously reported presence of 4.1B mRNA in the adrenal gland of
mouse fetus [38]. The adrenal medulla is composed of chromafﬁn
cells, and stimulated to secrete catecholamines through elaborate
mechanisms upon a “ﬁght or ﬂight” response [39]. The intercellular
spaces among adrenal chromafﬁn cells are believed to be crucial for
the transport of the secreted catecholamines and also for intercellular
communication [40]. Although expression of some cell adhesion
molecules such as NCAM and L1 are reported in the adrenal medulla,
the precise structural and molecular basis for maintaining those
structures are not well understood. TSLC1 expression was already
reported in several organs, including testes, kidneys, and lungs
[35,41,42], and TSLC1 is known to be involved in Ca2+-independent
intercellular junctions, which is critical in spermatogenesis of mouse
testes [35,43,44]. Given that 4.1B is involved in the intercellularjunctional complex through interaction with transmembranous
proteins such as Caspr in the nervous system [5], our results suggest
a physiological association between 4.1B and TSLC1 in the adrenal
medulla as well as in cancer cells [23], and also the potential
involvement of 4.1B in the intercommunication among adjacent
chromafﬁn cells. At the same time, other new functions of the TSLC1–
4.1B interaction should be also evaluated in further studies. For
example, NCAM-deﬁciency resulted in impaired granule trafﬁcking
rather than morphological abnormalities [37], although a signiﬁcant
difference in the density of secretary granules could not be found in
our quantitative comparison (data not shown).
In the present study, immunoreactivity of 4.1B in chromafﬁn cells
was not detected on the side of endothelial cells. Expression of 4.1B
has been found in different epithelial cells, such as mammary,
intestinal and renal epithelial cells [8,11,15,45,46]. In all of these
cells, immunostaining for 4.1B was observed along lateral and basal
plasma membranes directly facing adjacent cells or extracellular
matrices. From these ﬁndings, it was considered that 4.1B would
stabilize molecules for attachment to adjacent structures, including
those against extracellular matrices [47]. This hypothesis is also
supported by the ﬁnding that deletion of the intracellular domain of
Caspr resulted in its impaired binding to 4.1B and abnormal
distribution in axonal cytoplasm [48]. On the other hand, adrenal
medulla is one of the organs with sinusoidal capillaries, and the
basement membranes are located between the fenestrated sinusoidal
endothelial cells and chromafﬁn cells [49]. In the pancreatic islets
where endocrine cells also have sinusoidal capillaries and basement
membranes on the side of endothelial cells [50], similar ﬁndings have
been observed [51]. Plasma membranes of β-cell on the side of
endothelial cells had less 4.1B immunoreactivity compared to those
facing adjacent endocrine cells. These ﬁndings suggest that the
distribution of 4.1B is signiﬁcantly inﬂuenced by the molecular
mechanisms of adhesion, which would be distinct on the side of
basement membrane facing endothelial cells in chromafﬁn cells. The
molecular complex of intercellular and/or cell-extracellular junctions
in adrenal medulla should be examined in future studies.
Although 4.1B has been implicated in carcinogenesis in several
organs, its expression was well maintained in rodent pheochromocy-
toma, and also 4.1B-knockout mice did not developed pheochromo-
cytoma by our examination. The possibility that some unknown
isoforms are initiated from unidentiﬁed initiation sites but undetect-
able with our antibody could not be excluded. However, known 4.1B
gene products from the two initiation sites, which are expressed in
brain and adrenal glands, are eliminated by the genetic mutation in
our knockout mice [33,52]. Our results were consistent with the
previous observation that a murine 4.1B-knockout model does not
produce increased incidence of cancer [24]. FERM and U2 domains of
4.1B are thought to be essential for growth suppression of menin-
gioma-derived cells [53], and post-translational methylation of
arginine residues is a proposed pathway of 4.1B-induced apoptosis
[54]. However, the mechanism by which 4.1B inﬂuences the
carcinogenesis in various organs is not well known. Our results
suggest that loss of 4.1B is not essential for the generation of
pheochromocytoma in the rodent adrenal gland, and one possible
explanation for this might be that rodent adrenal glands lack such
molecules related to the tumor suppressive functions of 4.1B in other
organs. Another possibility is that the tumor-suppressive function of
4.1B varies in different species (including humans), as we found that
immunoreactivity of 4.1B was signiﬁcantly decreased in human
pheochromocytomas compared with the residual part of the normal
adrenal medulla (Ohno et al. unpublished data). This possibility would
be supported by the distinctive immunolocalization of human 4.1B in
blood vessel walls [13], where immunoreactivity of rodent 4.1B could
not be observed. Recently, some reports suggested that 4.1B was
mainly involved in the progression or metastatic process of cancers,
rather than cancer generation [17,55]. Compared to several key
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Ret, Menin and NF1 [56,57], other genes involved in the generation
and behavior of sporadic pheochromocytomas are still poorly under-
stood. Further studies on the role of 4.1B in the progression or
metastasis of pheochromocytoma would be essential to elucidate the
functional signiﬁcance of 4.1B in the adrenal medulla.
In our present investigation, TSLC1 distributionwas not affected by
genetic ablation of 4.1B in mice. TSLC1 contains a domain essential for
its efﬁcient binding to 4.1B, and deletion of the domain causes
diminished binding to 4.1B [23]. However, although inhibition of actin
polymerization resulted in reduced immunoreactivity of 4.1B and
TSLC1 along cell membranes [23], dispensability of 4.1B on the
plasmalemmal localization of TSLC1 in vivo has remained unclear.
TSLC1 also contains the PSD-95, Discs Large, and Zona Occludens 1
(PDZ) binding motif in its C-terminal region which mediates the
binding to membrane-associated guanylate kinase homologs
(MAGuK) [58]. Our results in 4.1B-knockout mice showing that 4.1B
is not essential to the localization of TSLC1 along cell membranes
suggest that the PDZ domain in TSLC1 would compensate for the
linkage to the actin membrane skeleton via other cytoskeletal
molecules associated with MAGuKs. Further studies on TSLC1-binding
proteins including MAGuKs in adrenal medulla are needed to reveal
the interaction network responsible for the plasmalemmal distribu-
tion of TSLC1, which is considered to be crucial for its tumor-
suppressive function [22].
Another possible explanation for the lack of obvious phenotype
and unaffected distribution of TSLC1 is the compensatory effect of
other molecules in the protein 4.1 family. The protein 4.1 family is
composed of four homologous proteins, 4.1R, 4.1N, 4.1G and 4.1B. They
are characterized by three highly conservative domains; the FERM
domain, the spectrin-actin binding domain and the C-terminal
domain [52,59]. Multiple members of protein 4.1 family can be
expressed in single cells and localize in same areas of different organs,
which lead to the hypothesis of compensation among family members
[6,10,31,60–62]. In our studies, we found that immunoreactivity of
4.1N is detected along intercellular membranes of chromafﬁn cells in
mouse adrenal gland (Ohno et al., unpublished data). By our
observation, 4.1N did not co-immunoprecipitated with TSLC-1, and
the immunoreactivity of 4.1N did not signiﬁcantly change in the 4.1B-
knockout mice. However, single binding proteins can interact with
different members of protein 4.1 family via highly conserved domains
[5,47], and 4.1B is considered to associate with TSLC1 via the FERM
domain [5,23,52,59]. Further studies, such as genetic ablation of 4.1N
in 4.1B knockout mice, would be necessary to examine the
compensatory role among protein 4.1 family more precisely. In
addition, potential expression of protein 4.1 family isoforms which
could not be detected in our paradigm should be explored in future
studies.
In conclusion, although expression and plasmalemmal localization
of 4.1B were shown in chromafﬁn cells of rodent adrenal medulla, the
expression of 4.1B wasmaintained in developed pheochromocytomas,
and generation of pheochromocytomas in 4.1B-deﬁcient mice could
not be detected in our studies. Furthermore, interaction and
colocalization of 4.1B and TSLC1 were observed in the adrenal
medulla, but 4.1B was not essential for the immunolocalization of
TSLC1 along chromafﬁn cell membranes. These results suggest that
the function of 4.1B as a tumor suppressor might differ signiﬁcantly
among organs and species, and that retention of TSLC1 on the cell
membranes would be maintained by interacting molecules other than
4.1B in rodent chromafﬁn cells.Acknowledgements
This workwas partially supported by a grant from Japan Society for
the Promotion of Science (#18590181) to N.T and a grant from theNational Cancer Institute (5P01CA023767) to F.C. We thank Dr.
Christopher Nelson for his careful editing of this manuscript.
References
[1] V.M. Braga, Cell–cell adhesion and signalling, Curr. Opin. Cell Biol. 14 (2002)
546–556.
[2] C. Jamora, E. Fuchs, Intercellular adhesion, signalling and the cytoskeleton, Nat.
Cell Biol. 4 (2002) E101–E108.
[3] M. Perez-Moreno, C. Jamora, E. Fuchs, Sticky business: orchestrating cellular
signals at adherens junctions, Cell 112 (2003) 535–548.
[4] C. Revenu, R. Athman, S. Robine, D. Louvard, The co-workers of actin ﬁlaments:
from cell structures to signals, Nat. Rev. Mol. Cell Biol. 5 (2004) 635–646.
[5] N. Deisenko-Nehrbass, K. Oguievetskaia, L. Goutebroze, T. Galvez, H. Yamakawa, O.
Ohara, M. Carnaud, J.A. Girault, Protein 4.1B associates with both Caspr/paranodin
and Caspr2 at paranodes and juxtaparanodes of myelinated ﬁbres, Eur. J. Neurosci.
17 (2003) 411–416.
[6] R. Ohara, H. Yamakawa, M. Nakayama, O. Ohara, Type II brain 4.1 (4.1B/KIAA0987),
a member of the protein 4.1 family, is localized to neuronal paranodes, Brain Res.
Mol. Brain Res. 85 (2000) 41–52.
[7] H. Yamakawa, O. Ohara, Comparison of mRNA and protein levels of four members
of the protein 4.1 family: the type II brain 4.1/4.1B/KIAA0987 is the most
predominant member of the protein 4.1 family in rat brain, Gene 248 (2000)
137–145.
[8] M. Ramez, M. Blot-Chabaud, F. Cluzeaud, S. Chanan, M. Patterson, L.D. Walensky, S.
Marfatia, A.J. Baines, J.A. Chasis, J.G. Conboy, N. Mohandas, P. Gascard, Distinct
distribution of speciﬁc members of protein 4.1 gene family in the mouse nephron,
Kidney Int. 63 (2003) 1321–1337.
[9] N. Terada, N. Ohno, H. Yamakawa, T. Baba, Y. Fujii, O. Ohara, S. Ohno, Protein 4.1B
localizes on unmyelinated axonal membranes in the mouse enteric nervous
system, Neurosci. Lett. 366 (2004) 15–17.
[10] N. Terada, N. Ohno, H. Yamakawa, T. Baba, Y. Fujii, Z. Zea, O. Ohara, S. Ohno,
Immunohistochemical study of protein 4.1B in the normal and W/W(v) mouse
seminiferous epithelium, J. Histochem. Cytochem. 52 (2004) 769–777.
[11] N. Terada, N. Ohno, H. Yamakawa, G. Seki, Y. Fujii, T. Baba, O. Ohara, S. Ohno,
Immunoelectron microscopic localization of protein 4.1B in proximal S1 and S2
tubules of rodent kidneys, Med. Electron Microsc. 37 (2004) 45–51.
[12] Y.K. Tran, O. Bogler, K.M. Gorse, I. Wieland, M.R. Green, I.F. Newsham, A novel
member of the NF2/ERM/4.1 superfamily with growth suppressing properties in
lung cancer, Cancer Res. 59 (1999) 35–43.
[13] D.H. Gutmann, J. Donahoe, A. Perry, N. Lemke, K. Gorse, K. Kittiniyom, S.A. Rempel,
J.A. Gutierrez, I.F. Newsham, Loss of DAL-1, a protein 4.1-related tumor suppressor,
is an important early event in the pathogenesis of meningiomas, Hum. Mol. Genet.
9 (2000) 1495–1500.
[14] A.L. Charboneau, V. Singh, T. Yu, I.F. Newsham, Suppression of growth and
increased cellular attachment after expression of DAL-1 in MCF-7 breast cancer
cells, Int. J. Cancer 100 (2002) 181–188.
[15] N. Ohno,N. Terada, S.Murata, H. Yamakawa, I.F. Newsham, R. Katoh, O. Ohara, S. Ohno,
Immunolocalization of protein4.1B/DAL-1during neoplastic transformation ofmouse
and human intestinal epithelium, Histochem. Cell Biol. 122 (2004) 579–586.
[16] P.K. Singh, D.H. Gutmann, C.E. Fuller, I.F. Newsham, A. Perry, Differential
involvement of protein 4.1 family members DAL-1 and NF2 in intracranial and
intraspinal ependymomas, Mod. Pathol. 15 (2002) 526–531.
[17] S.Y. Wong, H. Haack, J.L. Kissil, M. Barry, R.T. Bronson, S.S. Shen, C.A. Whittaker, D.
Crowley, R.O. Hynes, Protein 4.1B suppresses prostate cancer progression and
metastasis, Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 12784–12789.
[18] G. Heller, K.M. Fong, L. Girard, S. Seidl, A. End-Pfutzenreuter, G. Lang, A.F. Gazdar,
J.D. Minna, C.C. Zielinski, S. Zochbauer-Muller, Expression andmethylation pattern
of TSLC1 cascade genes in lung carcinomas, Oncogene 25 (2006) 959–968.
[19] G. Heller, J. Geradts, B. Ziegler, I. Newsham, M. Filipits, E.M. Markis-Ritzinger, D.
Kandioler, W. Berger, W. Stiglbauer, D. Depisch, R. Pirker, C.C. Zielinski, S.
Zochbauer-Muller, Downregulation of TSLC1 and DAL-1 expression occurs
frequently in breast cancer, Breast Cancer Res. Treat. 103 (2007) 283–291.
[20] S.S. Houshmandi, E.I. Surace, H.B. Zhang, G.N. Fuller, D.H. Gutmann, Tumor
suppressor in lung cancer-1 (TSLC1) functions as a glioma tumor suppressor,
Neurology 67 (2006) 1863–1866.
[21] M. Kuramochi, H. Fukuhara, T. Nobukuni, T. Kanbe, T. Maruyama, H.P. Ghosh, M.
Pletcher, M. Isomura, M. Onizuka, T. Kitamura, T. Sekiya, R.H. Reeves, Y. Murakami,
TSLC1 is a tumor-suppressor gene in human non-small-cell lung cancer, Nat.
Genet. 27 (2001) 427–430.
[22] Y. Murakami, Involvement of a cell adhesion molecule, TSLC1/IGSF4, in human
oncogenesis, Cancer Sci. 96 (2005) 543–552.
[23] M. Yageta, M. Kuramochi, M. Masuda, T. Fukami, H. Fukuhara, T. Maruyama, M.
Shibuya, Y. Murakami, Direct association of TSLC1 and DAL-1, two distinct tumor
suppressor proteins in lung cancer, Cancer Res. 62 (2002) 5129–5133.
[24] C. Yi, J.H. McCarty, S.A. Troutman, M.S. Eckman, R.T. Bronson, J.L. Kissil, Loss of the
putative tumor suppressor band 4.1B/Dal1 gene is dispensable for normal develop-
ment and does not predispose to cancer, Mol. Cell. Biol. 25 (2005) 10052–10059.
[25] T. Tsujiuchi, E. Sugata, T. Masaoka, M. Onishi, H. Fujii, K. Shimizu, K. Honoki,
Expression and DNA methylation patterns of Tslc1 and Dal-1 genes in
hepatocellular carcinomas induced by N-nitrosodiethylamine in rats, Cancer Sci.
98 (2007) 943–948.
[26] V. Pace, E. Perentes, P.G. Germann, Pheochromocytomas and ganglioneuromas in
the aging rats: morphological and immunohistochemical characterization,
Toxicol. Pathol. 30 (2002) 492–500.
515N. Ohno et al. / Biochimica et Biophysica Acta 1793 (2009) 506–515[27] C.L. Smith-Hicks, K.C. Sizer, J.F. Powers, A.S. Tischler, F. Costantini, C-cell
hyperplasia, pheochromocytoma and sympathoadrenal malformation in a
mouse model of multiple endocrine neoplasia type 2B, EMBO J. 19 (2000)
612–622.
[28] M. Komada, P. Soriano, Hrs, a FYVE ﬁnger protein localized to early endosomes, is
implicated in vesicular trafﬁc and required for ventral folding morphogenesis,
Genes Dev. 13 (1999) 1475–1485.
[29] Z. Li, N. Ohno, N. Terada, S. Ohno, Immunolocalization of serum proteins in living
mouse glomeruli under various hemodynamic conditions by “in vivo cryotechni-
que”, Histochem. Cell Biol. 126 (2006) 399–406.
[30] N. Ohno, N. Terada, S. Ohno, Histochemical analyses of living mouse liver under
different hemodynamic conditions by “in vivo cryotechnique”, Histochem. Cell
Biol. 126 (2006) 389–398.
[31] N. Terada, N. Ohno, H. Yamakawa, O. Ohara, X. Liao, T. Baba, S. Ohno,
Immunohistochemical study of a membrane skeletal molecule, protein 4.1G, in
mouse seminiferous tubules, Histochem. Cell Biol. 124 (2005) 303–311.
[32] N. Ohno, N. Terada, S. Saitoh, S. Ohno, Extracellular space in mouse cerebellar
cortex revealed by in vivo cryotechnique, J. Comp. Neurol. 505 (2007) 292–301.
[33] P. Gascard, M.K. Parra, Z. Zhao, V.R. Calinisan, W. Nunomura, S.A. Rivkees, N.
Mohandas, J.G. Conboy, Putative tumor suppressor protein 4.1B is differentially
expressed in kidney and brain via alternative promoters and 5′ alternative
splicing, Biochim. Biophys. Acta 1680 (2004) 71–82.
[34] R. Kannan, N.J. Grant, D. Aunis, K. Langley, SNAP-25 is differentially expressed by
noradrenergic and adrenergic chromafﬁn cells, FEBS Lett. 385 (1996) 159–164.
[35] T. Shingai, W. Ikeda, S. Kakunaga, K. Morimoto, K. Takekuni, S. Itoh, K. Satoh, M.
Takeuchi, T. Imai, M. Monden, Y. Takai, Implications of nectin-like molecule-2/
IGSF4/RA175/SgIGSF/TSLC1/SynCAM1 in cell-cell adhesion and transmembrane
protein localization in epithelial cells, J. Biol. Chem. 278 (2003) 35421–35427.
[36] A. Fritz, A. Walch, K. Piotrowska, M. Rosemann, E. Schaffer, K. Weber, A. Timper, G.
Wildner, J. Graw, H. Hoﬂer, M.J. Atkinson, Recessive transmission of a multiple
endocrine neoplasia syndrome in the rat, Cancer Res. 62 (2002) 3048–3051.
[37] S.A. Chan, L. Polo-Parada, L.T. Landmesser, C. Smith, Adrenal chromafﬁn cells
exhibit impaired granule trafﬁcking in NCAM knockout mice, J. Neurophysiol. 94
(2005) 1037–1047.
[38] M. Parra, P. Gascard, L.D. Walensky, J.A. Gimm, S. Blackshaw, N. Chan, Y. Takakuwa,
T. Berger, G. Lee, J.A. Chasis, S.H. Snyder, N. Mohandas, J.G. Conboy, Molecular and
functional characterization of protein 4.1B, a novel member of the protein 4.1
family with high level, focal expression in brain, J. Biol. Chem. 275 (2000)
3247–3255.
[39] A.G. Garcia, A.M. Garcia-De-Diego, L. Gandia, R. Borges, J. Garcia-Sancho, Calcium
signaling and exocytosis in adrenal chromafﬁn cells, Physiol. Rev. 86 (2006)
1093–1131.
[40] I. Benedeczky, P. Somogyi, Ultrastructure of the adrenal medulla of normal and
insulin-treated hamsters, Cell Tissue Res. 162 (1975) 541–550.
[41] S. Kikuchi, D. Yamada, T. Fukami, T. Maruyama, A. Ito, H. Asamura, Y. Matsuno, M.
Onizuka, Y. Murakami, Hypermethylation of the TSLC1/IGSF4 promoter is
associated with tobacco smoking and a poor prognosis in primary nonsmall cell
lung carcinoma, Cancer 106 (2006) 1751–1758.
[42] T. Wakayama, K. Ohashi, K. Mizuno, S. Iseki, Cloning and characterization of a
novel mouse immunoglobulin superfamily gene expressed in early spermatogenic
cells, Mol. Reprod. Dev. 60 (2001) 158–164.
[43] W.L. van der, M.J. Arends, O.E. Chausiaux, P.J. Ellis, U.C. Lange, M.A. Surani, N.
Affara, Y. Murakami, D.J. Adams, A. Bradley, Loss of TSLC1 causes male infertility
due to a defect at the spermatid stage of spermatogenesis, Mol. Cell. Biol. 26
(2006) 3595–3609.
[44] D. Yamada, M. Yoshida, Y.N. Williams, T. Fukami, S. Kikuchi, M. Masuda, T.
Maruyama, T. Ohta, D. Nakae, A. Maekawa, T. Kitamura, Y. Murakami, Disruption of
spermatogenic cell adhesion and male infertility in mice lacking TSLC1/IGSF4, animmunoglobulin superfamily cell adhesion molecule, Mol. Cell. Biol. 26 (2006)
3610–3624.
[45] R. Kuns, J.L. Kissil, I.F. Newsham, T. Jacks, D.H. Gutmann, L.S. Sherman, Protein 4.1B
expression is induced inmammary epithelial cells during pregnancy and regulates
their proliferation, Oncogene 24 (2005) 6502–6515.
[46] N. Terada, N. Ohno, S. Saitoh, G. Seki, M. Komada, T. Suzuki, H. Yamakawa, M.
Soleimani, S. Ohno, Interaction of membrane skeletal protein, protein 4.1B and
p55, and sodium bicarbonate cotransporter1 in mouse renal S1–S2 proximal
tubules, J. Histochem. Cytochem. 55 (2007) 1199–1206.
[47] J.H. McCarty, A.A. Cook, R.O. Hynes, An interaction between {alpha}v{beta}8
integrin and Band 4.1B via a highly conserved region of the Band 4.1 C-terminal
domain, Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 13479–13483.
[48] L. Gollan, H. Sabanay, S. Poliak, E.O. Berglund, B. Ranscht, E. Peles, Retention of a
cell adhesion complex at the paranodal junction requires the cytoplasmic region
of Caspr, J. Cell Biol. 157 (2002) 1247–1256.
[49] R.E. Coupland, Electron microscopic observations on the structure of the rat
adrenal medulla. I. The ultrastructure and organization of chromafﬁn cells in the
normal adrenal medulla, J. Anat. 99 (1965) 231–254.
[50] P.E. Lacy, W.S. Hartroft, Electron microscopy of the islets of Langerhans, Ann. N. Y.
Acad. Sci. 82 (1959) 287–301.
[51] N. Terada, N. Ohno, H. Yamakawa, T. Baba, Y. Fujii, G. Christofori, O. Ohara, S. Ohno,
Protein 4.1B in mouse islets of Langerhans and beta-cell tumorigenesis,
Histochem. Cell Biol. 120 (2003) 277–283.
[52] M. Parra, S. Gee, N. Chan, D. Ryaboy, I. Dubchak, N. Mohandas, P.D. Gascard, J.G.
Conboy, Differential domain evolution and complex RNA processing in a family of
paralogous EPB41 (protein 4.1) genes facilitate expression of diverse tissue-
speciﬁc isoforms, Genomics 84 (2004) 637–646.
[53] V.A. Robb, M.A. Gerber, E.K. Hart-Mahon, D.H. Gutmann, Membrane localization of
the U2 domain of Protein 4.1B is necessary and sufﬁcient for meningioma growth
suppression, Oncogene 24 (2005) 1946–1957.
[54] W. Jiang, I.F. Newsham, The tumor suppressor DAL-1/4.1B and protein
methylation cooperate in inducing apoptosis in MCF-7 breast cancer cells,
Mol. Cancer 5 (2006) 4.
[55] T. Cavanna, E. Pokorna, P. Vesely, C. Gray, D. Zicha, Evidence for protein 4.1B acting
as a metastasis suppressor, J. Cell Sci. 120 (2007) 606–616.
[56] C. Jimenez, G. Cote, A. Arnold, R.F. Gagel, Review: should patients with apparently
sporadic pheochromocytomas or paragangliomas be screened for hereditary
syndromes? J. Clin. Endocrinol. Metab. 91 (2006) 2851–2858.
[57] A. Karagiannis, D.P. Mikhailidis, V.G. Athyros, F. Harsoulis, Pheochromocytoma: an
update on genetics and management, Endocr. Relat Cancer 14 (2007) 935–956.
[58] H. Fukuhara, M. Masuda, M. Yageta, T. Fukami, M. Kuramochi, T. Maruyama, T.
Kitamura, Y. Murakami, Association of a lung tumor suppressor TSLC1 with MPP3,
a human homologue of Drosophila tumor suppressor Dlg, Oncogene 22 (2003)
6160–6165.
[59] C.X. Sun, V.A. Robb, D.H. Gutmann, Protein 4.1 tumor suppressors: getting a FERM
grip on growth regulation, J. Cell. Sci. 115 (2002) 3991–4000.
[60] L.D. Walensky, S. Blackshaw, D. Liao, C.C. Watkins, H.U. Weier, M. Parra, R.L.
Huganir, J.G. Conboy, N. Mohandas, S.H. Snyder, A novel neuron-enriched homolog
of the erythrocyte membrane cytoskeletal protein 4.1, J. Neurosci. 19 (1999)
6457–6467.
[61] F. Delhommeau, C. Vasseur-Godbillon, P. Leclerc, P.O. Schischmanoff, L. Croisille, P.
Rince, M. Morinière, E.J. Benz, G. Tchernia, G. Tamagnini, L. Ribeiro, J. Delaunay, F.
Baklouti, A splicing alteration of 4.1R pre-mRNA generates 2 protein isoforms with
distinct assembly to spindle poles in mitotic cells, Blood 100 (2002) 2629–2636.
[62] Z.T. Shi, V. Afzal, B. Coller, D. Patel, J.A. Chasis, M. Parra, G. Lee, C. Paszty, M. Stevens,
L. Walensky, L.L. Peters, N. Mohandas, E. Rubin, J.G. Conboy, Protein 4.1R-deﬁcient
mice are viable but have erythroid membrane skeleton abnormalities, J. Clin.
Invest. 103 (1999) 331–340.
